Singlera Genomics and its partner Breakthrough Genomics this week announced a research collaboration with the University of Pittsburgh around the early detection of pancreatic cancer.

The Chinese University of Hong Kong (CUHK) said Wednesday that it has struck a deal with startup MicroSigX Biotech Diagnostic to offer an investigational microbiome test for autism to 200 eligible children under a pilot project.

Helio Genomics said Monday that it has partnered to offer its LiverTrace at-home blood test for liver cancer in partnership with liver health telemedicine firm LiverRight.

German diagnostic startup Amplifold said Wednesday that it has raised €5 million ($5.8 million) in an oversubscribed seed financing round.

Natera announced last Friday that it has acquired cancer diagnostic firm Foresight Diagnostics for $275 million upfront.

Bengaluru-based deep-tech startup Morphle Labs has raised USD 5 million in a Series A round led by Inflexor Ventures to expand its physical AI-based automation systems for cancer diagnostics.

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025.

Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 28, 2025.

At the annual IDWeek meeting (https://idweek.org/), Bruker announced the U.S. Food and Drug Administration (FDA) clearance of Claim 7 and Claim 8 for its MALDI Biotyper® CA System, marking a significant advancement in clinical microbial identification capabilities. The clearance includes the MBT Compass HT CA software and MBT FAST™ Shuttle US IVD (Claim 7), as well as a major expansion of the FDA-cleared reference library (Claim 8), now encompassing 549 clinically validated microbial species across gram-positive and gram-negative bacteria, anaerobes and yeasts.

Private equity group Warburg Pincus is nearing a deal to take a large minority stake in French diagnostics group Sebia, which values the business at €5.4bn, according to people familiar with the matter.